Skip to main content
A
NYSE Life Sciences

$950 Million All-Cash Deal: Agilent to Acquire Biocare Medical

feedReported by Reuters
Sentiment info
Neutral
Importance info
8
Price
$116.64
Mkt Cap
$32.963B
52W Low
$96.43
52W High
$160.27
Market data snapshot near publication time

summarizeSummary

Agilent Technologies announced an all-cash agreement to acquire privately held clinical pathology firm Biocare Medical for $950 million. This strategic acquisition expands Agilent's footprint in the life sciences sector, representing a material investment for the company. While the article also mentioned Universal Health Services' (UHS) acquisition of Talkspace, that information was previously disclosed via an 8-K filing on March 9th, making it redundant. For Agilent, this new deal could impact future growth and financial performance, and investors will be watching for integration details and expected synergies.

At the time of this announcement, A was trading at $116.64 on NYSE in the Life Sciences sector, with a market capitalization of approximately $33B. The 52-week trading range was $96.43 to $160.27. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.


show_chartPrice Chart

Share this article

Copied!

feed A - Latest Insights

A
Mar 26, 2026, 8:49 AM EDT
Source: dpa-AFX
Importance Score:
7
A
Mar 20, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
A
Mar 10, 2026, 5:48 AM EDT
Source: Reuters
Importance Score:
8
A
Mar 09, 2026, 3:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
A
Feb 25, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
A
Jan 23, 2026, 7:00 AM EST
Filing Type: PRE 14A
Importance Score:
8